TEVA-ATOMOXETINE 10 MG
ATOMOXETINE (ATOMOXETINE HYDROCHLORIDE) : 10 MG · DIN 02314541 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-ATOMOXETINE?
TEVA-ATOMOXETINE 10 MG contains ATOMOXETINE (ATOMOXETINE HYDROCHLORIDE) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02314541, held by TEVA CANADA LIMITED, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 01-Jun-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-ATOMOXETINE used for?
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children 6 years of age and over, adolescents, and adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02314541 |
|---|---|
| Brand name | TEVA-ATOMOXETINE |
| Generic / active ingredient | ATOMOXETINE (ATOMOXETINE HYDROCHLORIDE) : 10 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 10 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06BA09 ATOMOXETINE |
| AHFS class | 28:92.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Jun-2012 |
| Original market date | 2010-09-16 00:00:00 |
How is it administered?
Administered orally once or twice daily. Dosage based on body weight for children/adolescents up to 70kg (start 0.5mg/kg, target 1.2mg/kg). Adults/over 70kg start 40mg, target 80mg. Max 100mg/day.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text (Table of Contents points to page 35, but text ends earlier).
How is it supplied?
Not explicitly detailed in the provided text summary, though strengths 10mg to 100mg are listed.
Contraindications
Hypersensitivity to atomoxetine; MAOI use within 2 weeks; Pheochromocytoma; Narrow angle glaucoma; Symptomatic cardiovascular disease; Severe cardiovascular disorders; Hypertension; Arteriosclerosis.
Warnings and precautions
Potential for suicide-related events; severe liver injury; increased blood pressure/heart rate; psychotic or manic symptoms; aggressive behavior; peripheral vasculopathy; priapism.
Is ATOMOXETINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 19 May 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N06BA09 ATOMOXETINE. 57 of 96 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-ATOMOXETINE | 10 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02318024 |
| APO-ATOMOXETINE | 100 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02318083 |
| APO-ATOMOXETINE | 18 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02318032 |
| APO-ATOMOXETINE | 25 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02318040 |
| APO-ATOMOXETINE | 40 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02318059 |
| APO-ATOMOXETINE | 60 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02318067 |
| APO-ATOMOXETINE | 80 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02318075 |
| ATOMOXETINE | 10 MG | CAPSULE | PRO DOC LIMITEE | MARKETED | DIN 02396904 |
| ATOMOXETINE | 10 MG | CAPSULE | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02445883 |
| ATOMOXETINE | 10 MG | CAPSULE | SANIS HEALTH INC | MARKETED | DIN 02467747 |
Who else supplies ATOMOXETINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ATOMOXETINE appears in 3558 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.